BE898418A - Composition stable pour corticotherapie locale. - Google Patents
Composition stable pour corticotherapie locale. Download PDFInfo
- Publication number
- BE898418A BE898418A BE0/212017A BE212017A BE898418A BE 898418 A BE898418 A BE 898418A BE 0/212017 A BE0/212017 A BE 0/212017A BE 212017 A BE212017 A BE 212017A BE 898418 A BE898418 A BE 898418A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- hydrocortisone
- composition
- solvent mixture
- propylene glycol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 32
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 21
- 239000003246 corticosteroid Substances 0.000 claims abstract description 11
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 11
- 239000011877 solvent mixture Substances 0.000 claims abstract description 10
- HCFAJYNVAYBARA-UHFFFAOYSA-N 4-heptanone Chemical compound CCCC(=O)CCC HCFAJYNVAYBARA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 8
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 5
- 239000002453 shampoo Substances 0.000 claims description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 2
- WQIAKSRYDHIZDB-UHFFFAOYSA-N 2-hydroxybenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC=C1O WQIAKSRYDHIZDB-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 208000037182 Hypertrophic Cicatrix Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010041303 Solar dermatitis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 206010033898 parapsoriasis Diseases 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/13—Burn treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU84515A LU84515A1 (fr) | 1982-12-09 | 1982-12-09 | Composition stable pour corticotherapie locale a forte concentration hydrocortisone solubilisee |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE898418A true BE898418A (fr) | 1984-06-08 |
Family
ID=19729992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE0/212017A BE898418A (fr) | 1982-12-09 | 1983-12-08 | Composition stable pour corticotherapie locale. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4853379A (en:Method) |
| JP (1) | JPS59112920A (en:Method) |
| BE (1) | BE898418A (en:Method) |
| CH (1) | CH656532A5 (en:Method) |
| DE (1) | DE3344439A1 (en:Method) |
| FR (1) | FR2537437B1 (en:Method) |
| GB (1) | GB2131692B (en:Method) |
| LU (1) | LU84515A1 (en:Method) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189066A (en) * | 1989-11-22 | 1993-02-23 | The Procter & Gamble Company | Pharmaceutical compositions of tebufelone |
| US5281420A (en) * | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
| US5632975A (en) * | 1995-03-09 | 1997-05-27 | Earles; R. Martin | Composition and method for treatment of dermatitis on the scalp |
| GB2302808A (en) * | 1995-07-04 | 1997-02-05 | Surtech Int Ltd | Propylene glycol with low potency corticosteroids for topical treatment of the scalp |
| FR2761600B1 (fr) | 1998-06-19 | 2000-03-31 | Oreal | Composition moussante pour le lavage et le traitement des cheveux et/ou du cuir chevelu a base d'un principe actif, d'un tensioactif anionique, d'un tensioactif amphotere et d'un agent propenetrant |
| US6723714B2 (en) * | 1999-07-06 | 2004-04-20 | Blansett Pharmacal Co., Inc. | Aqueous solvent for corticosteroids |
| US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
| WO2004060347A2 (en) * | 2002-09-03 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical propylene glycol solvate compositions |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US20090088443A1 (en) * | 2002-02-15 | 2009-04-02 | Julius Remenar | Novel crystalline forms of conazoles and methods of making and using the same |
| EP1494998A2 (en) * | 2002-03-01 | 2005-01-12 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| MXPA05000232A (es) | 2002-06-21 | 2005-06-17 | Transform Pharmaceuticals Inc | Composiciones farmaceuticas con disolucion mejorada. |
| AU2003267231A1 (en) * | 2002-09-20 | 2004-04-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
| US20060148877A1 (en) * | 2002-11-26 | 2006-07-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations of celcoxib |
| US8183290B2 (en) * | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
| US20050043283A1 (en) * | 2003-08-22 | 2005-02-24 | L'oreal S.A. | Compositions containing topical active agents and pentylene glycol |
| US20060018852A1 (en) * | 2003-08-22 | 2006-01-26 | L'oreal | Compositions containing topical active agents and pentylene glycol |
| FR2911781B1 (fr) | 2007-01-26 | 2009-03-20 | Fabre Pierre Dermo Cosmetique | Emulsion dermatologique et procede de preparation |
| JP7092498B2 (ja) * | 2017-12-28 | 2022-06-28 | 小林製薬株式会社 | 尿かぶれ改善剤 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA986441A (en) * | 1971-10-22 | 1976-03-30 | Aslam Khwaja | Enzyme treatment |
| US4009254A (en) * | 1974-05-06 | 1977-02-22 | Colgate-Palmolive Company | Topical compositions |
| US4082881A (en) * | 1976-12-23 | 1978-04-04 | E. R. Squibb & Sons, Inc. | Topical and other type pharmaceutical formulations containing isosorbide carrier |
| CH634480A5 (de) * | 1977-11-25 | 1983-02-15 | Schwarzkopf Gmbh Hans | Unter druck stehendes aerosolpraeparat. |
| US4323558A (en) * | 1979-09-10 | 1982-04-06 | Nelson Research & Development Co. | Topical trien containing pharmaceutical compositions and methods of use |
| US4289764A (en) * | 1979-12-04 | 1981-09-15 | Drythanol Ltd. | Steroid compositions |
| US4311517A (en) * | 1980-03-03 | 1982-01-19 | Shell Oil Company | Reducing the effect, in plants, of ice-promoting nuclei originating from certain bacteria |
| US4305936A (en) * | 1980-10-09 | 1981-12-15 | Dermik Laboratories | Topical corticosteroid formulations |
| US4353896A (en) * | 1981-06-08 | 1982-10-12 | Levy Michael A | Penetrating topical medicament |
-
1982
- 1982-12-09 LU LU84515A patent/LU84515A1/fr unknown
-
1983
- 1983-12-08 FR FR838319663A patent/FR2537437B1/fr not_active Expired
- 1983-12-08 BE BE0/212017A patent/BE898418A/fr not_active IP Right Cessation
- 1983-12-08 JP JP58230725A patent/JPS59112920A/ja active Granted
- 1983-12-08 DE DE19833344439 patent/DE3344439A1/de active Granted
- 1983-12-08 CH CH6581/83A patent/CH656532A5/fr not_active IP Right Cessation
- 1983-12-08 GB GB08332803A patent/GB2131692B/en not_active Expired
-
1986
- 1986-10-15 US US06/918,978 patent/US4853379A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0347252B2 (en:Method) | 1991-07-18 |
| DE3344439A1 (de) | 1984-06-14 |
| JPS59112920A (ja) | 1984-06-29 |
| GB8332803D0 (en) | 1984-01-18 |
| CH656532A5 (fr) | 1986-07-15 |
| US4853379A (en) | 1989-08-01 |
| LU84515A1 (fr) | 1984-10-22 |
| FR2537437B1 (fr) | 1985-07-26 |
| GB2131692B (en) | 1986-05-21 |
| GB2131692A (en) | 1984-06-27 |
| FR2537437A1 (fr) | 1984-06-15 |
| DE3344439C2 (en:Method) | 1992-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE898418A (fr) | Composition stable pour corticotherapie locale. | |
| CA2165613C (fr) | Composition cosmetique, dermatologique ou pharmaceutique stable contenant du disulfure de selenium et au moins un sel de zinc | |
| EP0680745B1 (fr) | Utilisation de composés antifongiques et de composés antibactériens halogénés pour diminuer la chute des cheveux | |
| EP0317846B1 (fr) | Compositions pharmaceutiques et cosmétiques à base de peroxyde de benzoyle et de salicylates lipophiles d'ammonium quaternaires et leur utilisation, notamment dans le traitement de l'acné | |
| BE898268A (fr) | Nouvelle composition anti-acneique à base de peroxyde de benzoyle et d'au moins un autre principe actif. | |
| LU86756A1 (fr) | Compositions cosmetiques non agressives contenant un tensio-actif moussant et un tensio-actif non ionique a deux chaines grasses | |
| FR2474312A1 (fr) | Nouvelles compositions anti-microbiennes pour le traitement topique de l'acne vulgaire | |
| CA1179271A (fr) | Composition epaissie anhydre, stable a l'oxydation, a base d'anthraline ou de l'un de ses derives dans un support constitue d'un alkyl ester d'acide gras et d'un agent epaississant, et son utilisation dans le traitement des maladies de la peau | |
| EP0835652B1 (fr) | Utilisation d'au moins un glycol comme agent de solubilisation de la mélatonine dans l'eau et compositions les contenant | |
| CA1099636A (en) | Dithranol composition for the treatment of psoriasis | |
| LU86844A1 (fr) | Utilisation a titre de produit cosmetique d'un complexe cuivrique de l'acide 3,5-diisopropyl salicylique et compositions cosmetiques pour la protection de l'epiderme humain contre le rayonnement uv contenant ce compose | |
| FR2693206A1 (fr) | Utilisation dans des solutions d'agents tensioactifs de carbamates d'aminopolyols en tant qu'épaississants et compositions les contenant. | |
| BE898417A (fr) | Composition stable pour corticotherapie locale contenant a l'etat solubilise de l'hydrocortisone. | |
| FR2827768A1 (fr) | Composition cosmetique moussante pour le bain | |
| CA1083482A (fr) | Lotion demaquillante pour les yeux | |
| JPH07187946A (ja) | 頭皮外用剤組成物 | |
| JPS61249912A (ja) | カチオン界面活性剤組成物 | |
| FR2569561A1 (fr) | Composition stable d'anthraline dans des triglycerides d'acides gras satures d'origine vegetale ayant de 6 a 12 atomes de carbone | |
| BE1000153A4 (fr) | Composition anti-acneique stable a base d'erythromycine. | |
| JPH0212925B2 (en:Method) | ||
| JP3270789B2 (ja) | 養毛剤 | |
| JPS59210010A (ja) | ヘア・ロ−シヨン | |
| JP2869168B2 (ja) | 育毛剤及びそれを含有する養毛化粧料 | |
| FR2458281A2 (fr) | Compositions cosmetiques pour cheveux, contenant des polymeres quaternises, et procede pour leur application | |
| WO1982004190A1 (fr) | Compositions cosmetiques a application topique dans le traitement de la seborrhee |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: S.A. L OREAL Effective date: 19921231 |